Your Dedicated Partner for

Expert Phage Display Solutions

At Cell Origins, our leading scientists offer innovative and tailored phage display services, delivered through a boutique, one-on-one client experience focused on achieving excellent and impactful results for your research.

LEARN MORE

ABOUT US

At Cell Origins, we believe discovery is personal. As a boutique contract research organization specializing in peptide and antibody discovery through phage display, we combine world-class scientific expertise with one-on-one collaboration. Every project we take on is a true partnership — tailored to your goals, fueled by precision, and driven by a shared commitment to innovation. With a flexible model and a focus on unmatched quality, we deliver solutions that larger CROs simply can’t replicate.


Cell Origins was founded by scientists trained directly under the pioneers of phage display at the University of Missouri  — where the technology was first developed by George Smith who later received the Nobel prize for his work. With over 40 years of combined experience, our team brings deep expertise, hands-on innovation, and a personal commitment to excellence. We offer more than technical services: we build true partnerships, working closely with each client to tailor discovery strategies that drive real results. At Cell Origins, every project is grounded in innovation  — and in a shared passion for advancing the next generation of peptides and antibodies.

At Cell Origins, we stand behind every discovery. As founders, we personally commit to delivering the highest standards of scientific rigor, innovation, and service. Your success is our mission

OUR EXPERTISE

Decades of Discovery. Precision in every partnership.

ORIGIN STORIES

Exploring the moments that spark new possibilities

  • PUBLICATION | Improving Pharmacokinetics of Peptides Using Phage Display

    Optimization of the desired pharmacokinetic properties should be an important consideration in biopanning strategies to enable the selection of peptides and peptide-conjugated nanoparticles that effectively target biomarkers in vivo.

    More
  • BLOG ARTICLE | Best Practices in Phage Display: Optimizing Binding Affinity

    Achieving ligands with the highest possible binding affinity requires careful attention to detail and adherence to best practices throughout the process. Here, we explore key strategies for optimizing binding affinity during phage display biopanning.

    More
  • BLOG ARTICLE | Best Practices in Phage Display: Looking Beyond Binding Affinity

    The true challenge of peptide discovery often lies beyond the basics of achieving high binding affinity- success depends on carefully managing key parameters such as off-target binding, biodistribution, and pharmacokinetics.

    More
  • DECK | Cell Origins 2025

    Explore our service capabilities and case studies.

    More
  • BLOG ARTICLE | Radiopharmaceuticals: The Road Ahead

    Radiopharmaceuticals are heralding a transformative era in cancer therapy, leveraging innovative approaches to target tumor cells with remarkable precision. Yet, as with any groundbreaking technology, the path to widespread implementation presents both immense opportunities and notable challenges.

    More